Puma Biotechnology (PBYI) Q2 2025 earnings summary

Executive summary

• Q2 2025 net income was $5.9 million GAAP ($0.12/share) and $7.5 million non-GAAP ($0.15/share), reversing prior year losses and exceeding Q1 2025 results.

• Total Q2 2025 revenue reached $52.4 million, with net product revenue from NERLYNX at $49.2 million and royalty revenue at $3.2 million, both up year-over-year and quarter-over-quarter.

• Commercial focus remains on expanding NERLYNX utilization, especially for high-risk HER2-positive early breast cancer, and advancing alisertib clinical trials in breast and lung cancer.

• Net cash provided by operating activities increased to $14.1 million in Q2 2025, with cash, equivalents, and marketable securities totaling $96 million at June 30, 2025.

• Operating expenses decreased, mainly due to lower legal fees and stock-based compensation, while R&D expenses rose with faster clinical trial enrollment.

Financial highlights

• NERLYNX net product revenue grew 11% year-over-year to $49.2 million in Q2 2025; royalty revenue was $3.2 million.

• Gross revenue from NERLYNX sales was $62.1 million, up from $54.4 million in Q1 2025.

• Cost of sales rose to $12.3 million, including $2.4 million in amortization of intangible assets.

• SG&A expenses were $18 million in Q2 2025, down year-over-year, while R&D expenses increased to $15.5 million.

• Cash, cash equivalents, and marketable securities totaled $96 million at June 30, 2025, with $45 million in outstanding principal debt.

Outlook and guidance

• FY 2025 net NERLYNX product revenue expected between $192 million and $198 million; total revenue guidance is $212–$222 million.

• FY 2025 net income guidance is $23 million–$28 million; gross-to-net adjustment expected at 21.5%–22% for the year.

• Q3 2025 net product revenue expected at $46 million–$48 million; Q3 net income guidance is $2 million–$4 million.

• Royalty revenue for FY 2025 expected at $20 million–$24 million, lower due to fewer China shipments.

• Key clinical milestones for alisertib trials in breast and lung cancer expected in Q4 2025.